Basel Life Sciences Hub Partners with Korean Biopharmas

The Basel Area is strengthening its global position as a leading biotech hub through a new partnership with major South Korean biopharma organizations. Basel Area Business & Innovation announced a strategic collaboration aimed at helping Korean biotech companies expand into international markets.

The initiative brings together key partners including Roche Korea, Korea Health Industry Development Institute, and Korea Technology Finance Corporation. The collaboration focuses on accelerating growth opportunities for high-potential biopharma companies, particularly targeting expansion into the United States and other global markets.

Officials described the partnership as a new model of international ecosystem building. It combines market access, industry expertise, and funding support to create faster pathways for innovation-driven companies. The program will officially launch in May 2026 as a joint open innovation initiative.

Each partner will play a distinct role in the program. Roche Korea will lead company selection and explore opportunities for mentorship and collaboration. KHIDI will identify promising companies and support program operations, while KIBO will evaluate participants and facilitate access to financing. Meanwhile, Basel Area Business & Innovation will connect selected firms with infrastructure and networks within the region.

The collaboration will also provide access to the Switzerland Innovation Park Basel Area, one of Europe’s most concentrated life sciences ecosystems. This infrastructure offers startups and scaleups the resources needed to grow rapidly in a competitive global environment.

Industry leaders emphasized that innovation is increasingly global, and partnerships like this help bridge regions. By linking Korean biotech innovators with Basel’s established ecosystem, the initiative aims to accelerate breakthroughs and strengthen international cooperation.

The program is expected to evolve into a flagship initiative, deepening ties between South Korea and global biotech markets while positioning Basel as a gateway for life sciences innovation.